Eli Lilly Launches Discounted Mounjaro And Zepbound As Fight Against Compounded Imitations Escalates Amid Ongoing FDA Shortage Status Debate
Eli Lilly Launches Discounted Mounjaro And Zepbound As Fight Against Compounded Imitations Escalates Amid Ongoing FDA Shortage Status Debate
伊利·莉莉推出了打折的蒙加羅和澤普寶作爲對原料物複製品爆發升級的反擊，此舉是在持續的FDA物品短缺狀態辯論中進行的。
Eli Lilly (NYSE:LLY) is intensifying its efforts to combat imitation versions of its popular appetite-suppressing drugs, Mounjaro and Zepbound.
禮來（紐交所:LLY）正在加大力度打擊其知名的抑食藥物Mounjaro和Zepbound的仿製品。
What Happened: The pharmaceutical giant is seeking to end a regulatory designation that has permitted cheaper, off-brand versions to thrive. Lawyers for Eli Lilly have notified healthcare providers that shortages of Mounjaro and Zepbound are effectively over, despite the FDA not yet confirming this status, reported The Washington Post.
發生了什麼：這家藥品巨頭正尋求結束一個允許廉價、非品牌版本繁榮的監管定義。據《華盛頓郵報》報道，禮來的律師已通知醫療服務提供者，Mounjaro和Zepbound的短缺問題已基本解決，儘管FDA尚未確認這種狀態。
On Tuesday, Eli Lilly launched a discounted product, presenting it as a safer alternative to the off-brand medications. This move comes as the company faces competition from compounding...
禮來週二推出了一種折扣產品，將其作爲非品牌藥物的更安全替代...
登入免費觀看全文
登入/註冊